Every material Form 8-K MapLight Therapeutics, Inc. has filed with the SEC since June 22, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
MapLight agreed to sell 9,197,887 shares and pre-funded warrants for 3,983,168 shares to institutional investors at $11.38 per share, for gross proceeds of approximately $150.0 million before fees, with closing expected on August 14, 2026. The company also reported a second-quarter net loss of $60.2 million, up from $29.8 million a year earlier, and says the financing and existing cash of $351.3 million should fund its lead program through 2028, which means existing shareholders will be diluted.
Private placement of 9,197,887 common shares and pre-funded warrants for 3,983,168 shares at $11.38 per share; gross proceeds of approximately $150.0 million before fees
Expected closing on August 14, 2026; placement agents are Morgan Stanley, Jefferies, Leerink Partners and Stifel
Q2 2026 net loss of $60.2 million vs. $29.8 million in Q2 2025; R&D expenses rose to $53.4 million from $26.8 million
Cash, cash equivalents and investments of $351.3 million at June 30, 2026; company expects runway through 2028 including the private placement proceeds
MapLight Therapeutics reported topline results from ZEPHYR, a Phase 2 trial of ML-007C-MA in hospitalized adults with schizophrenia experiencing an acute exacerbation of psychosis, on July 27, 2026. The 210/3 mg twice-daily dose met the primary endpoint, reducing PANSS total score by 4.5 points more than placebo at Week 5, while the 330/6 mg once-daily arm did not reach statistical significance. The company plans to discuss next steps with the FDA at an end-of-phase 2 meeting before a further pivotal trial.
210/3 mg BID arm: PANSS total score down 4.5 points versus placebo at Week 5 (p=0.015), meeting the primary endpoint
330/6 mg QD arm: 2.8 points versus placebo, p=0.110, not statistically significant
Prespecified cognitive composite score improved in the baseline-impaired subgroup (effect size 0.51, p=0.041)
Company plans to engage the FDA at an end-of-phase 2 meeting and identify sites for an additional pivotal trial
MapLight Therapeutics reported topline results from its Phase 2 IRIS trial of ML-004 in autism spectrum disorder, announced June 22, 2026. The study did not meet its primary endpoint on social communication deficits, but a prespecified analysis in adolescents with moderate-to-severe irritability showed improvement over placebo, and the company plans to meet with the FDA to determine the development path.
Primary endpoint (ABI-SC social communication domain) was not met; no statistical separation from placebo on that measure.
In adolescents with baseline ABC-I score of 16 or higher (N=20), care-partner-reported ABC-I improved over placebo: effect size 1.33, nominal p=0.013.
Two adolescents (3.9%) on ML-004 discontinued due to an adverse event versus none on placebo; no severe or serious adverse events occurred with ML-004.
The company expects to engage the FDA in an End-of-Phase 2 meeting; the trial enrolled 161 participants, including 102 adolescents.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MapLight Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →